{"id":497406,"date":"2020-07-21T13:14:01","date_gmt":"2020-07-21T13:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=497406"},"modified":"2020-07-21T13:14:01","modified_gmt":"2020-07-21T13:14:01","slug":"castratesensitive-prostate-cancer-cspc-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/castratesensitive-prostate-cancer-cspc-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_497406.html","title":{"rendered":"Castrate-Sensitive Prostate Cancer (CSPC) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"
\"Castrate-Sensitive<\/a><\/p>\n
\n
“Castrate-Sensitive Prostate Cancer (CSPC) Market Insights, Epidemiology and Market Forecast \u2013 2030”<\/div>\n<\/div>\n<\/div>\n

DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on “Castrate-Sensitive Prostate Cancer (CSPC) Market Insights, Epidemiology and Market Forecast – 2030<\/strong>” to its portfolio.<\/p>\n

 <\/p>\n

DelveInsight’s ‘Castrate-Sensitive Prostate Cancer (CSPC) Market Insights, Epidemiology and Market Forecast – 2030<\/a>’<\/strong> report delivers an in-depth understanding of the CSPC, historical and forecasted epidemiology as well as the CSPC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/p>\n

 <\/p>\n

Key Highlights from report are:<\/strong><\/p>\n

1. The market size of CSPC in the 7MM countries is expected to increase by 2030 from USD 638 million in 2017, which is expected to increase during study period (2017–2030).<\/p>\n

2. The total cases of CSPC in the 7MM were found to be 763,077 in 2017 which is expected to grow during the study period, i.e., 2017–2030.<\/p>\n

3. The total prevalent cases of prostate cancer in the 7MM were observed to be 6,742,385 cases in 2017. Among patients, about 40% of them have mild IBS, 35% suffer from moderate IBS, and 25% from severe IBS,<\/p>\n

 <\/p>\n

Request for Sample Pages: https:\/\/www.delveinsight.com\/sample-request\/castrate-sensitive-prostate-cancer-market<\/a><\/strong><\/p>\n

 <\/p>\n

Key benefits of the Report<\/strong><\/p>\n

1. Castrate-Sensitive Prostate Cancer (CRPC) market report covers a descriptive overview and comprehensive insight of the Castrate- Sensitive Prostate Cancer (CRPC) epidemiology and Castrate- Sensitive Prostate Cancer (CRPC) market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Castrate- Sensitive Prostate Cancer (CRPC) market report provides insights on the current and emerging therapies.
3. Castrate- Sensitive Prostate Cancer (CRPC) market report offers a global historical and forecasted market covering drug outreach in 7 MM.
4. Castrate- Sensitive Prostate Cancer (CRPC) market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Castrate- Sensitive Prostate Cancer (CRPC) market.<\/p>\n

 <\/p>\n

Prostate cancer<\/strong><\/a> is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm.<\/p>\n

According to the Cancer Treatment Centres of America (CTCA), more than 99% of prostate cancers are adenocarcinomas, which develop in the gland cells.<\/p>\n

The exact cause of prostate cancer is unknown. However, several things can increase the risk of developing this condition like age, family history, diet, high testosterone level, genome changes, and race.<\/p>\n

Many patients undergo regular prostate cancer screening before symptoms appear. Screening may involve one or more of the following tests: prostate-specific antigen (PSA), digital rectal exam (DRE),prostate ultrasound, prostate MRI,prostate Mp-MRI.<\/p>\n

Treatment strategies of prostate cancers depend on the stage and progression of cancer. For localized or locally advanced prostate cancer active surveillance, surgery, and radiation therapy is the three major treatment options.<\/p>\n

Besides, this other treatment options for prostate cancers include chemotherapy, hormone therapy, and immunotherapy. Hormonal therapy has been a mainstay in the treatment of advanced prostate cancer.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for Sample Pages: https:\/\/www.delveinsight.com\/sample-request\/castrate-sensitive-prostate-cancer-market<\/a><\/strong><\/p>\n

 <\/p>\n

“According to the analysis, it was estimated that prostate cancer is more prevalent in people of age between 65–74 years followed by 55–64 years and 75–84 years.”<\/strong><\/em><\/p>\n

 <\/p>\n

Drugs covered in the report are:-<\/strong><\/p>\n

There are several key players robustly involved in developing potential products such as<\/p>\n

1. Keytruda (Pembrolizumab\/MK-3475) + Enzalutamide + ADT
2. Opdivo (nivolumab) ± ADT ± docetaxel ± Ipilimumab
3. Relugolix
4. ProstAtak (AdV-tk + valacyclovir)
5. PRX302 (topsalysin)
6. RV001
And Many Others<\/p>\n

 <\/p>\n

Key Players covered in the report are:-<\/strong><\/p>\n

1. Merck Sharp & Dohme
2. Bristol-Myers Squibb
3. Myovant Sciences
4. Sophiris Bio
5. Advantagene
And many others<\/p>\n

 <\/p>\n

Request for Sample Pages: https:\/\/www.delveinsight.com\/sample-request\/castrate-sensitive-prostate-cancer-market<\/a><\/strong><\/p>\n

 <\/p>\n

Reasons to buy<\/strong><\/p>\n

1. The report will help in developing business strategies by understanding trends shaping and driving the CSPC market.
2. To understand the future market competition in the CSPC market and Insightful review of the key market drivers and barriers.
3. Organize sales and marketing efforts by identifying the best opportunities for CSPC in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
4. Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
5. Organize sales and marketing efforts by identifying the best opportunities for CSPC market.
6. To understand the future market competition in the CSPC market.<\/p>\n

 <\/p>\n

Table of Contents<\/strong><\/p>\n

 <\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary of CSPC\/HSPC<\/p>\n

3. SWOT Analysis of CSPC\/HSPC<\/p>\n

4. CSPC\/HSPC: Market Overview at a Glance<\/p>\n

5. CSPC\/HSPC: Disease Background and Overview<\/p>\n

5.1. Introduction<\/p>\n

5.1.1. Signs and Symptoms of Prostate Cancer<\/p>\n

5.1.2. Risk Factors and Causes of Prostate Cancer<\/p>\n

5.1.3. Pathophysiology of Prostate Cancer<\/p>\n

5.1.4. Prostate Neoplasia<\/p>\n

5.1.5. Genetics of Prostate Cancer<\/p>\n

6. Diagnosis<\/p>\n

6.1. Screening Tests for Prostate Cancer<\/p>\n

6.2. Tests to Diagnose Prostate Cancer<\/p>\n

6.3. Stages and Grades of Prostate Cancer<\/p>\n

7. Epidemiology and Patient Population<\/p>\n

7.1. Key Findings<\/p>\n

7.2. Assumptions and Rationale: 7MM<\/p>\n

7.3. Epidemiology Scenario: 7MM<\/p>\n

7.3.1. Total Prevalent Cases of Prostate Cancer in the 7MM<\/p>\n

7.3.2. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM<\/p>\n

7.3.3. Total Non-metastatic and Metastatic Cases of CSPC\/HSPC in the 7MM<\/p>\n

7.3.4. Total Treated cases of Non-metastatic CSPC\/HSPC Patients in the 7MM<\/p>\n

7.3.5. Total Treated Cases of Metastatic CSPC\/HSPC Patients in the 7MM<\/p>\n

7.4. The United States Epidemiology<\/p>\n

7.4.1. Total Diagnosed Cases of Prostate Cancer in the United States<\/p>\n

7.4.2. Age-specific Cases of Prostate Cancer in the United States<\/p>\n

7.4.3. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States<\/p>\n

7.4.4. Total Non-metastatic and Metastatic Cases of CSPC\/HSPC in the United States<\/p>\n

7.4.5. Total Treated cases of Non-metastatic CSPC\/HSPC in the United States<\/p>\n

7.4.6. Total Treated Cases of Metastatic CSPC\/HSPC in the United States<\/p>\n

8. EU-5 Country-wise Epidemiology<\/p>\n

8.1. Germany<\/p>\n

8.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Germany<\/p>\n

8.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany<\/p>\n

8.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany<\/p>\n

8.1.4. Total Non-metastatic and Metastatic Cases of CSPC\/HSPC in Germany<\/p>\n

8.1.5. Total Treated cases of Non-metastatic CSPC\/HSPC in Germany<\/p>\n

8.1.6. Total Treated Cases of Metastatic CSPC\/HSPC in Germany<\/p>\n

8.2. France<\/p>\n

8.2.1. Total Diagnosed Prevalent cases of Prostate Cancer in France<\/p>\n

8.2.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in France<\/p>\n

8.2.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France<\/p>\n

8.2.4. Total Non-metastatic and Metastatic Cases of CSPC\/HSPC in France<\/p>\n

8.2.5. Total Treated cases of Non-metastatic CSPC\/HSPC in France<\/p>\n

8.2.6. Total Treated Cases of Metastatic CSPC\/HSPC in France<\/p>\n

8.3. Italy<\/p>\n

8.3.1. Total Diagnosed Prevalent cases of Prostate Cancer in Italy<\/p>\n

8.3.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy<\/p>\n

8.3.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy<\/p>\n

8.3.4. Total Non-metastatic and Metastatic Cases of CSPC\/HSPC in Italy<\/p>\n

8.3.5. Total Treated cases of Non-metastatic CSPC\/HSPC in Italy<\/p>\n

8.3.6. Total Treated Cases of Metastatic CSPC\/HSPC in Italy<\/p>\n

8.4. Spain<\/p>\n

8.4.1. Total Diagnosed Prevalent cases of Prostate Cancer in Spain<\/p>\n

8.4.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain<\/p>\n

8.4.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain<\/p>\n

8.4.4. Total Non-metastatic and Metastatic Cases of CSPC\/HSPC in Spain<\/p>\n

8.4.5. Total Treated cases of Non-metastatic CSPC\/HSPC in Spain<\/p>\n

8.4.6. Total Treated Cases of Metastatic CSPC\/HSPC in Spain<\/p>\n

8.5. United Kingdom<\/p>\n

8.5.1. Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom<\/p>\n

8.5.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom<\/p>\n

8.5.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom<\/p>\n

8.5.4. Total Non-metastatic and Metastatic Cases of CSPC\/HSPC in the United Kingdom<\/p>\n

8.5.5. Total Treated cases of Non-metastatic CSPC\/HSPC in the United Kingdom<\/p>\n

8.5.6. Total Treated Cases of Metastatic CSPC\/HSPC in the United Kingdom<\/p>\n

9. Japan<\/p>\n

9.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Japan<\/p>\n

9.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan<\/p>\n

9.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan<\/p>\n

9.1.4. Total Non-metastatic and Metastatic Cases of CSPC\/HSPC in Japan<\/p>\n

9.1.5. Total Treated cases of Non-metastatic CSPC\/HSPC in Japan<\/p>\n

9.1.6. Total Treated Cases of Metastatic CSPC\/HSPC in Japan<\/p>\n

10. Current Treatment Practices: Prostate Cancer<\/p>\n

10.1. Treatment Algorithm of Prostate Cancer<\/p>\n

10.2. Observation or Active Surveillance<\/p>\n

10.3. Surgery<\/p>\n

10.3.1. Open or Laparoscopic Radical Prostatectomy<\/p>\n

10.3.2. Risks of Prostate Surgery<\/p>\n

10.4. Radiation Therapy<\/p>\n

10.4.1. Types of Radiation Therapy<\/p>\n

10.5. Hormone Therapy<\/p>\n

10.5.1. Types of Hormone Therapy<\/p>\n

10.6. Immunotherapy<\/p>\n

10.6.1. Vaccine<\/p>\n

10.6.2. Immune checkpoint inhibitors<\/p>\n

10.7. Chemotherapy<\/p>\n

11. Guideline of Prostate Cancer<\/p>\n

11.1. TheEuropean Association of Urology (EAU) Guideline for Management of Prostate Cancer: 2020<\/p>\n

11.2. The National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer: 2019<\/p>\n

11.2.1. Screening Guidelines<\/p>\n

11.2.2. Genetic Testing<\/p>\n

11.2.3. Bone Scan for Diagnosis of Metastatic Disease<\/p>\n

11.3. Japanese Urological Association Clinical Practice Guideline for Prostate Cancer<\/p>\n

12. Unmet Needs of Prostate Cancer<\/p>\n

13. Marketed Therapies<\/p>\n

13.1. Key Cross<\/p>\n

13.2. Xtandi (Enzalutamide): Astellas Pharma<\/p>\n

13.2.1. Product Description<\/p>\n

13.2.2. Regulatory Milestones<\/p>\n

13.2.3. Other Developmental Activities<\/p>\n

13.2.4. Pivotal Clinical Trial<\/p>\n

13.2.5. Ongoing Current Pipeline Activity<\/p>\n

13.3. Erleada (apalutamide): Janssen Pharmaceutical<\/p>\n

13.3.1. Product Description<\/p>\n

13.3.2. Regulatory Milestones<\/p>\n

13.3.3. Other Developmental Activities<\/p>\n

13.3.4. Pivotal Clinical Trials<\/p>\n

13.3.5. Ongoing Current Pipeline Activity<\/p>\n

14. Emerging Therapies<\/p>\n

14.1. Opdivo (nivolumab): Bristol-Myers Squibb<\/p>\n

14.1.1. Product Description<\/p>\n

14.1.2. Clinical Development<\/p>\n

14.1.3. Safety and Efficacy<\/p>\n

14.2. Relugolix: Myovant Sciences\/Takeda<\/p>\n

14.2.1. Product Description<\/p>\n

14.2.2. Clinical Development<\/p>\n

14.2.3. Safety and Efficacy<\/p>\n

14.3. Keytruda (Pembrolizumab\/MK-3475): Merck Sharp & Dohme<\/p>\n

14.3.1. Product Description<\/p>\n

14.3.2. Clinical Development<\/p>\n

14.3.3. Safety and Efficacy<\/p>\n

14.4. PRX302 (topsalysin): Sophiris Bio<\/p>\n

14.4.1. Product Description<\/p>\n

14.4.2. Clinical Development<\/p>\n

14.4.3. Safety and Efficacy<\/p>\n

14.5. RV001V: RhoVac<\/p>\n

14.5.1. Product Description<\/p>\n

14.5.2. Other Developmental Activities<\/p>\n

14.5.3. Clinical Development<\/p>\n

14.5.4. Safety and Efficacy<\/p>\n

14.6. ProstAtak: Advantagene<\/p>\n

14.6.1. Product Description<\/p>\n

14.6.2. Other Developmental Activities<\/p>\n

14.6.3. Clinical Development<\/p>\n

14.6.4. Safety and Efficacy<\/p>\n

15. CSPC\/HSPC: Seven Major Market Analysis<\/p>\n

15.1. Key Findings<\/p>\n

15.2. Market Outlook: 7MM<\/p>\n

16. 7MM Market Size<\/p>\n

16.1. Total Market Size of CSPC in the 7MM<\/p>\n

16.2. Total Market size of CSPC by Therapies in the 7MM<\/p>\n

16.3. United States Market Size<\/p>\n

16.3.1. Total Market size of CSPC in the United States<\/p>\n

16.3.2. Total Market size of CSPC by Therapies in the United States<\/p>\n

16.4. EU-5 Market Size<\/p>\n

16.4.1. Germany Market Size<\/p>\n

16.4.2. France Market Size<\/p>\n

16.4.3. Italy Market Size<\/p>\n

16.4.4. Spain Market Size<\/p>\n

16.4.5. United Kingdom Market Size<\/p>\n

16.5. Japan Market Size<\/p>\n

16.5.1. Total Market size of CSPC in Japan<\/p>\n

16.5.2. Total Market size of CSPC by Therapies in Japan<\/p>\n

17. Market Access and Reimbursement of CSPC<\/p>\n

18. Market Drivers of CSPC<\/p>\n

19. Market Barriers of CSPC<\/p>\n

20. Appendix<\/p>\n

20.1. Bibliography<\/p>\n

20.2. Report Methodology<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About DelveInsight<\/p>\n

 <\/p>\n

 <\/p>\n

Request for detailed TOC : https:\/\/www.delveinsight.com\/sample-request\/castrate-sensitive-prostate-cancer-market<\/strong><\/p>\n

 <\/p>\n

Related reports:<\/strong><\/p>\n

Prostate cancer- Market Insight, Epidemiology and Market Forecast -2030<\/strong><\/p>\n

DelveInsight’s “Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Ankit Nigam
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/report-store\/castrate-sensitive-prostate-cancer-market<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Castrate-Sensitive Prostate Cancer (CSPC) Market Insights, Epidemiology and Market Forecast \u2013 2030” DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on “Castrate-Sensitive Prostate Cancer (CSPC) Market Insights, Epidemiology and Market Forecast – 2030” to its portfolio. … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,413],"tags":[],"class_list":["post-497406","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=497406"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497406\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=497406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=497406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=497406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}